(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 October 2010 (21.10.2010)

PCT

(10) International Publication Number
WO 2010/120614 A1

(51) **International Patent Classification**:
A61K 31/5517 (2006.01) *A61P 35/02* (2006.01)

(21) **International Application Number**:
PCT/US2010/030315

(22) **International Filing Date**:
8 April 2010 (08.04.2010)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/169,094 14 April 2009 (14.04.2009) US

(71) **Applicant** *(for all designated States except US)*: **ELI LILLY AND COMPANY** [US/US]; Lilly Corporate Center, Indianapolis, Indiana 46285 (US).

(72) **Inventor; and**

(75) **Inventor/Applicant** *(for US only)*: **CHEDID, Marcio** [BR/US]; Eli Lilly And Company, Lilly Corporate Center, Indianapolis, Indiana 46285 (US).

(74) **Agents**: **DEMETER, John** et al.; ELI LILLY AND COMPANY, Patent Division, P. O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

WO 2010/120614 A1

(54) **Title**: BENZODIAZEPINE DERIVATIVE FOR THE TREATMENT OF HEMATOPOIETIC NEOPLASM AND LEUKEMIA

(57) **Abstract**: A method and medicament for treating mixed lineage leukemia; translocated mixed lineage leukemia; translocated mixed lineage leukemia based acute myelogenous leukemia; translocated mixed lineage leukemia based acute lymphoid leukemia; a non-MLL based chronic myeloproloferative disorder, or non-MLL based acoute lymphoid leukemia is provided, wherein the active agent used is the GSK-3 inhibitor 7- (2, 5-dihydro-4-imidazo [1, 2-a] pyridine-3-yl-2,5-dioxo-lH-pyrrol-3-yl) -9-fluoro-1,2,3, 4-tetrahydro-2- (1-piper idinylcarbonyl)-pyrrolo [3,2,1-jk] [1,4] benzodiazepine or a pharmaceutically acceptable salt or salvate thereof.